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This standard is based on CG31, CG113, CG123, CG159 and NG116.
This standard should be read in conjunction with QS48, QS50, QS8, QS14, QS15, QS71,
QS73, QS88, QS108, QS102, QS99, QS95, QS80, QS9, QS115 and QS175.
Introduction
This quality standard covers the identification and management of anxiety disorders in primary,
secondary and community care for children, young people and adults. For more information see the
anxiety disorders topic overview.
Anxiety disorders are types of common mental health disorders (depression is another type of
common mental health disorder). This quality standard covers a range of anxiety disorders,
including generalised anxiety disorder, social anxiety disorder, post-traumatic stress disorder, panic
disorder, obsessive–compulsive disorder and body dysmorphic disorder.
This quality standard does not explicitly address the management of generalised anxiety disorder
and panic disorder in children (younger than 16 years) because these were not covered in the
source guideline (NICE's guideline on generalised anxiety disorder and panic disorder in adults).
Why this quality standard is needed
Many anxiety disorders go unrecognised or undiagnosed. Most of those that are diagnosed are
treated in primary care. However, recognition of anxiety disorders in primary care is poor and only
a small minority of people experiencing anxiety disorders ever receive treatment. When anxiety
disorders coexist with depression, the depressive episode may be recognised without detecting the
underlying and more persistent anxiety disorder. For people who use services for anxiety disorders,
treatment is often limited to the prescription of drugs. This may be partly because evidence-based
psychological services are not universally available.
There is considerable variation in the severity of anxiety disorders, but they have been associated
with significant long-term disability. They can be distressing for the person affected, their families,
friends and carers, and can have an impact on their local communities. Anxiety disorders can have a
lifelong course of relapse and remission. They commonly occur together, or with other problems
such as depression or substance misuse.
The 1-week prevalence rates for adults (a snapshot of anxiety disorders over a 1-week period) from
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the Office of National Statistics 2007 national survey in England were 4.4% for generalised anxiety
disorder, 3.0% for post-traumatic stress disorder, 1.1% for panic disorder and 1.1% for
obsessive–compulsive disorder.
Generalised anxiety disorder is characterised by excessive worry about a number of different
events, associated with heightened tension. A person with generalised anxiety disorder may also
feel irritable and have physical symptoms such as restlessness, feeling easily tired and having tense
muscles. They may also have trouble concentrating or sleeping. For the disorder to be diagnosed,
symptoms should be present for at least 6 months and should cause clinically significant distress or
impairment in social, occupational or other important areas of functioning.
Panic disorder can be characterised by the presence of recurring, unforeseen panic attacks
followed by at least 1 month of persistent worry about having another panic attack and concern
about the consequences of a panic attack, or a significant change in behaviour related to the
attacks. At least 2 unexpected panic attacks are necessary for diagnosis and the attacks should not
be accounted for by the use of a substance, a general medical condition or another psychological
problem.
Obsessive–compulsive disorder is characterised by the presence of obsessions or compulsions, or
commonly both. An obsession is defined as an unwanted intrusive thought, image or urge that
repeatedly enters the person's mind. Compulsions are repetitive behaviours or mental acts that the
person feels driven to perform. The symptoms can cause significant functional impairment and
distress.
Post-traumatic stress disorder can develop after a stressful event or situation of an exceptionally
threatening or catastrophic nature that is likely to cause pervasive distress in almost anyone.
People might develop the disorder in response to 1 or more traumatic events such as deliberate
acts of interpersonal violence, severe accidents, disasters or military action. Post-traumatic stress
disorder does not develop after upsetting situations that are described as 'traumatic' in everyday
language, for example, divorce, loss of a job or failing an exam.
Social anxiety disorder (previously known as 'social phobia'), is persistent fear of or anxiety about
1 or more social situations that involve interaction, observation and performance that is out of
proportion to the actual threat posed by the social situation.
Most anxiety disorders have a relatively early age of onset, with symptoms and syndromes likely to
have started in childhood or adolescence. Anxiety disorders in children and young people
commonly run a chronic course and are associated with increased risk of other serious mental
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health problems, including depression and substance misuse. Thus early identification and
treatment of anxiety disorders in children and young people is important. Poor recognition,
inadequate assessment and limited awareness or availability of treatments may limit access to
effective interventions.
How this quality standard supports delivery of outcome frameworks
NICE quality standards are a concise set of prioritised statements designed to drive measureable
quality improvements within a particular area of health or care. They are derived from high-quality
guidance, such as that from NICE or other sources accredited by NICE. This quality standard, in
conjunction with the guidance on which it is based, should contribute to the improvements outlined
in the following 3 outcomes frameworks published by the Department of Health:
The Adult Social Care Outcomes Framework 2013–14 (Department of Health, November
2012)
NHS Outcomes Framework 2014–15
Improving outcomes and supporting transparency: a public health outcomes framework for
England 2013–2016, Part 1 and Part 1A.
Tables 1–3 show the outcomes, overarching indicators and improvement areas from the
frameworks that the quality standard could contribute to achieving.
Table 1 The Adult Social Care Outcomes Framework 2013–14
Domain Overarching and outcome measures
1 Enhancing quality of life
for people with care and
support needs
Overarching measure
1A Social care-related quality of life*
Outcome measures
People are able to find employment when they want, maintain a
family and social life and contribute to community life, and
avoid loneliness or isolation.
1F. Proportion of adults in contact with secondary mental
health services in paid employment***
1H. Proportion of adults in contact with secondary mental
health services living independently, with or without support**
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3 Ensuring that people have
a positive experience of care
and support
Overarching measure
People who use social care and their carers are satisfied with
their experience of care and support services.
3E. Improving people's experience of integrated care
(placeholder)**
Aligning across the health and care system
* Indicator complementary
** Indicator shared
*** Indicator complementary with the Public Health Outcomes Framework and the NHS
Outcomes Framework
Table 2 NHS Outcomes Framework 2014–15
Domain Overarching indicators and improvement areas
1 Preventing people from dying
prematurely
Overarching indicators
1a Potential Years of Life Lost (PYLL) from causes
considered amenable to healthcare
1b Life expectancy at 75 i males ii females
Improvement areas
Reducing premature death in people with serious
mental illness
1.5 Excess under 75 mortality rate in adults with
serious mental illness (PHOF 4.9*)
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2 Enhancing quality of life for people
with long-term conditions
Overarching indicator
2 Health related quality of life for people with long-
term conditions* (ASCOF 1A)
Improvement areas
Ensuring people feel supported to manage their
condition
2.1 Proportion of people feeling supported to
manage their condition
Improving functional ability in people with long-term
conditions
2.2 Employment of people with long-term conditions
(ASCOF 1E**, PHOF 1.6*)
Enhancing quality of life for people with mental
illness
2.5 Employment of people with mental illness
(ASCOF 1E**, PHOF 1.8**)
3 Helping people to recover from ill-
health or following injury
Improvement areas
Improving outcomes from planned treatments








4 Ensuring people have a positive
experience of care
Overarching indicators
4a Patient experience of primary care
i GP services ii GP out-of-hours services
4b Patient experience of hospital care
4c Friends and Family Test
Improvement areas
Improving people's experience of outpatient care
4.1 Patient experience of outpatient services
Improving hospitals' responsiveness to personal
needs
4.2 Responsiveness to in-patients' personal needs
Improving people's experience of accident and
emergency services
4.3 Patient experience of accident and emergency
services
Improving experience of healthcare for people with
mental illness
4.7 Patient experience of community mental health
services
Improving children and young people's experience of
healthcare
4.8 Children and young people's experience of outpatient
services
Improving people's experience of integrated care
4.9 People's experience of integrated care (ASCOF 3E**)
Alignment across the health and social care system
* Indicator is shared
** Indicator is complementary
Indicators in italics are placeholders, pending development or identification
Table 3 Public health outcomes framework for England, 2013-2016
Domain Objectives and indicators
Anxiety disorders (QS53)




1 Improving the wider
determinants of health
Objective
Improvements against wider factors that affect health and
wellbeing and health inequalities
Indicators
1.6 Adults with a learning disability/in contact with secondary
mental health services who live in stable and appropriate
accommodation†
1.7 People in prison who have a mental illness or a significant mental
illness (Placeholder)
Employment for those with a long-term health condition including
those with a learning difficulty/disability or mental illness
1.8 Employment for those with long-term health conditions
including adults with a learning disability or who are in contact with
secondary mental health services* †† **
1.9 Sickness absence rate
2 Health improvement Objective
People are helped to live healthy lifestyles, make healthy choices
and reduce health inequalities
Indicators







Reduced numbers of people living with preventable ill health and
people dying prematurely, while reducing the gap between
communities.
Indicators
4.9 Excess under 75 mortality rate in adults with serious mental
illness*
4.10 Suicide rate
4.13 Health-related quality of life for older people (Placeholder)
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alignment across the Health and Care System
* Indicator shared with the NHS Outcomes Framework
** Complementary to indicators in the NHS Outcomes Framework
† Indicator shared with the Adult Social Care Outcomes Framework
†† Complementary to indicators in the Adult Social Care Outcomes Framework
Indicators in italics are placeholders, pending development or identification
Coordinated services
The quality standard for anxiety disorders specifies that services should be commissioned from and
coordinated across all relevant agencies encompassing the whole anxiety disorders care pathway.
A person-centred, integrated approach to providing services is fundamental to delivering high-
quality care to people with anxiety disorders in primary and secondary care.
The Health and Social Care Act 2012 sets out a clear expectation that the care system should
consider NICE quality standards in planning and delivering services, as part of a general duty to
secure continuous improvement in quality. Commissioners and providers of health and social care
should refer to the library of NICE quality standards when designing high-quality services. Other
quality standards that should also be considered when choosing, commissioning or providing a
high-quality anxiety disorders service are listed in related quality standards.
Training and competencies
The quality standard should be read in the context of national and local guidelines on training and
competencies. All health, public health and social care professionals involved in assessing, caring
for and treating people with anxiety disorders should have sufficient and appropriate training and
competencies to deliver the actions and interventions described in the quality standard.
Role of families and carers
Quality standards recognise the important role families and carers have in supporting people with
anxiety disorders. If appropriate, health, public health and social care professionals should ensure
that family members and carers are involved in the decision-making process about assessment,
treatment and care.
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List of quality statements
Statement 1 People with a suspected anxiety disorder receive an assessment that identifies
whether they have a specific anxiety disorder, the severity of symptoms and associated functional
impairment.
Statement 2 People with an anxiety disorder are offered evidence-based psychological
interventions.
Statement 3 People with an anxiety disorder are not prescribed benzodiazepines or antipsychotics
unless specifically indicated.
Statement 4 People receiving treatment for an anxiety disorder have their response to treatment
recorded at each treatment session.
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Quality statement 1: Assessment of suspected anxiety disorders
Quality statement
People with a suspected anxiety disorder receive an assessment that identifies whether they have a
specific anxiety disorder, the severity of symptoms and associated functional impairment.
Rationale
Accurate diagnosis of a person's specific anxiety disorder can help them understand their condition
and ensure that they are offered the most appropriate treatment at the earliest opportunity.
Quality measures
Structure
a) Evidence of local arrangements for people with a suspected anxiety disorder to receive an
assessment that identifies whether they have a specific anxiety disorder, the severity of symptoms
and associated functional impairment.
Data source: Local data collection.
b) Evidence of local arrangements to ensure that healthcare professionals receive training to
perform assessments of anxiety disorders.
Data source: Local data collection.
Process
Proportion of people with a suspected anxiety disorder who receive an assessment that identifies
whether they have a specific anxiety disorder, the severity of symptoms and associated functional
impairment.
Numerator – the number of people in the denominator who receive an assessment that identifies
whether they have a specific anxiety disorder, the severity of symptoms and associated functional
impairment.
Denominator – the number of people with a suspected anxiety disorder.
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Data source: Local data collection.
What the quality statement means for service providers, healthcare
professionals and commissioners
Service providers ensure they provide services for people who have a suspected anxiety disorder
to diagnose specific anxiety disorders, and that the assessment services are delivered by fully
trained healthcare professionals.
Healthcare professionals carry out an assessment for people who have a suspected anxiety
disorder to diagnose specific anxiety disorders, or refer to a practitioner who is trained to carry out
such an assessment.
Commissioners ensure that they commission services that carry out assessments for people with a
suspected anxiety disorder to diagnose specific anxiety disorders.
What the quality statement means for service users and carers
Peoplewho may have an anxiety disorder are offered an assessment to find out whether they do
have an anxiety disorder, what type of disorder it is and the effect it may have on their everyday life.
Source guidance
Common mental health problems: identification and pathways to care (2011) NICE guideline
CG123, recommendations 1.3.2.4 and 1.3.2.6
Social anxiety disorder: recognition, assessment and treatment (2013) NICE guideline CG159,
recommendations 1.2.5 to 1.2.9 and 1.4.5 to 1.4.8
Definitions of terms used in this quality statement
Anxiety disorder
Anxiety disorders are generalised anxiety disorder, social anxiety disorder, post-traumatic stress
disorder, panic disorder, obsessive–compulsive disorder and body dysmorphic disorder.
Assessment of anxiety disorders
Assessment of anxiety disorders includes the nature, duration and severity of the presenting
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disorder and associated functional impairment. It also includes consideration of the ways in which
the following factors may have affected the development, course and severity of the disorder:
a history of any mental health disorder
a history of a chronic physical health problem
any past experience of, and response to, treatments
the quality of interpersonal relationships
living conditions and social isolation
a family history of mental illness
a history of domestic violence or sexual abuse
employment and immigration status.
[NICE's guideline on common mental health problems, recommendations 1.3.2.4 and 1.3.2.6]
A diagnostic or problem identification tool or algorithm may be used to inform the assessment.
[NICE's guideline on common mental health problems, recommendation 1.3.2.3, NICE's guideline
on social anxiety disorder, recommendations 1.2.7 and 1.4.9 to 1.4.12]
Assessment of social anxiety disorder
The assessment of social anxiety disorder is slightly different from assessment of other anxiety
disorders. It includes consideration of fear, avoidance, distress and functional impairment. It takes
into account comorbid disorders, including avoidant personality disorder, alcohol and substance
misuse, mood disorders, other anxiety disorders, psychosis and autism. A detailed description of
the person's current social anxiety and associated problems and circumstances is obtained,
including:
feared and avoided social situations
what they are afraid might happen in social situations (for example, looking anxious, blushing,
sweating, trembling or appearing boring)
anxiety symptoms
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focus of attention in social situations
anticipatory and post-event processing
occupational, educational, financial and social circumstances
family circumstances and support (for children and young people)
friendships and peer groups (for children and young people)
medication, alcohol and recreational drug use.
[NICE's guideline on social anxiety disorder, recommendations 1.2.5 to 1.2.9 and 1.4.5 to 1.4.8]
Suspected anxiety disorder
An anxiety disorder may be suspected in people with a past history of an anxiety disorder, possible
somatic symptoms of an anxiety disorder or recent experience of a traumatic event, and in people
who avoid social situations. It may be suspected because of the person's responses to initial
questions about their symptoms. The 2-item Generalized Anxiety Disorder scale may be used to
ask the person about their feelings of anxiety and their ability to stop or control worry.
[NICE's guideline on common mental health problems, recommendation 1.3.1]
Equality and diversity considerations
Consideration should be given to modifying the method and mode of delivery of assessment
according to the needs of the person with a suspected anxiety disorder. Technology should be
considered for people who may find it difficult to, or choose not to, attend a specific service, for
example people with social anxiety who are anxious about attending a healthcare service.
Communication needs should be considered for people who do not have English as their first
language, for example by providing bilingual therapists or independent translators.
For people with sensory impairment or a learning disability, use of the distress thermometer and
asking a family member or carer about the person's symptoms should be considered.
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When assessing people with a suspected anxiety disorder and a moderate to severe learning
disability or moderate to severe acquired cognitive impairment, consideration should be given to
consulting a relevant specialist.
Assessments should be culturally sensitive, using suitable explanatory models of common mental
health disorders and addressing any cultural and ethnic needs. Relevant information, including
cultural or other individual characteristics that may be important in subsequent care, should be
identified during assessment. For example, if the boundary between religious or cultural practice
and obsessive–compulsive symptoms is unclear, healthcare professionals should, with the service
user's consent, consider seeking the advice and support of an appropriate religious or community
leader to support the therapeutic process.
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Quality statement 2: Psychological interventions
Quality statement
People with an anxiety disorder are offered evidence-based psychological interventions.
Rationale
Evidence-based psychological interventions can be effective treatments for anxiety disorders.
They are recommended first-line treatments in preference to pharmacological treatment.
Healthcare professionals should usually offer or refer for the least intrusive, most effective
intervention first, in line with the stepped-care approach set out in the NICE guidance.
Quality measures
Structure
Evidence of local arrangements to ensure that people with an anxiety disorder are offered
evidence-based psychological interventions.
Data source: Local data collection.
Process
Proportion of people with an anxiety disorder who receive evidence-based psychological
interventions.
Numerator – the number of people in the denominator who receive evidence-based psychological
interventions.
Denominator – the number of people with an anxiety disorder.
Data source: Local data collection. National data are collected in the Improving Access to
Psychological Therapies (IAPT) Data Set and National Audit of Psychological Therapies for Anxiety
and Depression (standard 1b).
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What the quality statement means for service providers, healthcare
professionals and commissioners
Service providers ensure that they are able to provide evidence-based psychological interventions
to people who are referred to them with anxiety disorders.
Healthcare professionals ensure that they offer evidence-based psychological interventions to
people with anxiety disorders.
Commissioners ensure that they commission services from providers who are able to deliver
evidence-based psychological interventions to meet the needs of people with anxiety disorders.
What the quality statement means for service users and carers
People with an anxiety disorder are offered psychological treatments (sometimes called 'talking
treatments') that have been shown by evidence to be helpful for their disorder.
Source guidance
Common mental health problems: identification and pathways to care (2011) NICE guideline
CG123, recommendation 1.4.1.4
Obsessive-compulsive disorder and body dysmorphic disorder: treatment (2005) NICE
guideline CG31, recommendations 1.5.1.8, 1.5.1.9 (key priority for implementation) and
1.5.1.10 (key priority for implementation)
Post-traumatic stress disorder (2018) NICE guideline NG116, recommendations 1.6.6, 1.6.7
and 1.6.11
Social anxiety disorder: recognition, assessment and treatment (2013) NICE guideline 159,
recommendations 1.3.2 (key priority for implementation), 1.3.4 (key priority for
implementation), 1.3.7, 1.3.12, 1.5.3 (key priority for implementation) and 1.5.6
Definitions of terms used in this quality statement
Anxiety disorders
Anxiety disorders are generalised anxiety disorder, social anxiety disorder, post-traumatic stress
disorder, panic disorder, obsessive–compulsive disorder and body dysmorphic disorder.
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Evidence-based psychological interventions include both low-intensity interventions incorporating
self-help approaches and high-intensity psychological therapies.
For adults with generalised anxiety disorder, panic disorder, post-traumatic stress disorder,
obsessive–compulsive disorder or body dysmorphic disorder psychological interventions are
offered based on the stepped-care approach.
[NICE's guideline on common mental health problems, recommendation 1.4.1.4]
Cognitive behavioural therapy has been specifically developed to treat social anxiety disorder in
adults, children and young people.
[NICE's guideline on social anxiety disorder, recommendations 1.3.2 and 1.5.3]
Psychological therapies have been specifically developed to treat obsessive–compulsive disorder,
body dysmorphic disorder and post-traumatic stress disorder in children and young people.
[NICE's guidelines on obsessive-compulsive disorder and body dysmorphic disorder,
recommendations 1.5.1.9 and 1.5.1.10, and post-traumatic stress disorder, recommendation
1.6.11]
Equality and diversity considerations
For people with generalised anxiety disorder who have a learning disability or cognitive
impairment, methods of delivering treatment and treatment duration should be adjusted if
necessary to take account of the disability or impairment, with consideration given to consulting a
relevant specialist.
It is important that healthcare professionals familiarise themselves with the cultural background of
the person with an anxiety disorder. They should pay particular attention to identifying people with
post-traumatic stress disorder whose work or home culture is resistant to recognising the
psychological consequences of trauma.
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Quality statement 3: Pharmacological treatment
Quality statement
People with an anxiety disorder are not prescribed benzodiazepines or antipsychotics unless
specifically indicated.
Rationale
NICE guidance provides recommendations on pharmacological therapies for anxiety disorders.
Benzodiazepines are associated with tolerance and dependence, and antipsychotics are associated
with a number of adverse effects. Therefore they should not be used routinely to treat anxiety
disorders.
Healthcare professionals should be aware of circumstances in which benzodiazepines and
antipsychotics may be appropriate, such as short-term care and anxiety disorder crises.
Quality measures
Structure
Evidence of local monitoring arrangements to ensure that people with an anxiety disorder are not
prescribed a benzodiazepine or an antipsychotic to treat their disorder unless specifically
indicated.
Data source: Local data collection.
Process
a) Proportion of people who have an anxiety disorder and are prescribed a benzodiazepine that is
not specifically indicated.
Numerator – the number of people in the denominator for whom a benzodiazepine is not
specifically indicated.
Denominator – the number of people with an anxiety disorder who are prescribed a
benzodiazepine.
b) Proportion of people who have an anxiety disorder and are prescribed an antipsychotic that is
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Numerator – the number of people in the denominator for whom an antipsychotic is not specifically
indicated.
Denominator – the number of people with an anxiety disorder who are prescribed an antipsychotic.
Data source: Local data collection.
Outcome
a) Rates of prescribing benzodiazepines.
b) Rates of prescribing antipsychotics.
Data source: Local data collection.
What the quality statement means for service providers, healthcare
professionals and commissioners
Service providers ensure that there are procedures and protocols in place to monitor the
prescribing of pharmacological treatment for people with anxiety disorders to ensure that
benzodiazepines and antipsychotics are not offered to treat that disorder unless specifically
indicated.
Healthcare professionals ensure that people with anxiety disorders are not offered
benzodiazepines or antipsychotics to treat that disorder unless specifically indicated.
Commissioners ensure that they monitor rates of prescribing of benzodiazepines and
antipsychotics to treat anxiety disorders and only commission services from providers who can
demonstrate that they have procedures and protocols in place to monitor this prescribing.
What the quality statement means for service users and carers
People with an anxiety disorder are not offered benzodiazepines (medication used to help people
sleep or act as a sedative) or antipsychotics (medication used mainly to treat psychotic conditions
such as schizophrenia) for that disorder unless there are specific clinical reasons why these
treatments may be of short-term benefit.
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Obsessive-compulsive disorder and body dysmorphic disorder: treatment (2005) NICE
guideline CG31, recommendations 1.5.3.21, 1.5.3.22, and 1.5.6.21
Generalised anxiety disorder and panic disorder in adults: management (2011) NICE guideline
CG113, recommendations 1.2.25 (key priority for implementation), 1.4.7 and 1.4.8
Social anxiety disorder: recognition, assessment and treatment (2013) NICE guideline CG159,
recommendation 1.6.2
Definitions of terms used in this quality statement
Anxiety disorders
Anxiety disorders are generalised anxiety disorder, social anxiety disorder, post-traumatic stress
disorder, panic disorder, obsessive–compulsive disorder and body dysmorphic disorder.
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Quality statement 4: Monitoring treatment response
Quality statement
People receiving treatment for an anxiety disorder have their response to treatment recorded at
each treatment session.
Rationale
Regular monitoring of psychological and pharmacological treatment response ensures that the
effectiveness of treatment can be assessed and treatment adjusted if needed. It also provides an
opportunity for healthcare professionals to monitor other outcomes such as effects on any long-
term conditions and the person's ability to continue or return to employment.
Quality measures
Structure
Evidence of local arrangements to monitor response to treatment for people being treated for an
anxiety disorder at each treatment session and use the findings to adjust delivery of interventions.
Data source: Local data collection.
Process
Proportion of people receiving treatment for an anxiety disorder who have their response to
treatment recorded at initial contact and each subsequent treatment session.
Numerator – the number of people in the denominator whose response to treatment is recorded at
initial contact and each subsequent treatment session.
Denominator – the number of people receiving treatment for an anxiety disorder.
Data source: Local data collection. Routine outcome monitoring is part of the Improving Access to
Psychological Therapies (IAPT) Data Set, the Children and Young People's IAPT Programme and
the National Audit of Psychological Therapies for Anxiety and Depression (standard 9).
Anxiety disorders (QS53)





Evidence from feedback that people receiving treatment for an anxiety disorder are aware of their
progress.
Data source: Local data collection.
What the quality statement means for service providers, healthcare
professionals and commissioners
Service providers ensure that systems are in place to record response to treatment at each
treatment session for people receiving treatment for anxiety disorders.
Healthcare professionals ensure that they record response to treatment at each treatment session
for people receiving treatment for anxiety disorders and adjust treatment if needed.
Commissioners ensure that they commission services that record response to treatment at each
treatment session for people receiving treatment for anxiety disorders.
What the quality statement means for service users and carers
People who are receiving treatment for an anxiety disorder have a check at each treatment session
to find out how well their treatment is working and help decide how best to continue with their
treatment.
Source guidance
Common mental health problems: identification and pathways to care (2011) NICE guideline
CG123, recommendations 1.5.1.3 (key priority for implementation) and 1.5.1.10
Social anxiety disorder: recognition, assessment and treatment (2013) NICE guideline CG159,
recommendations 1.3.1 (key priority for implementation) and 1.5.1
Definitions
Anxiety disorders
Anxiety disorders are generalised anxiety disorder, social anxiety disorder, post-traumatic stress
disorder, panic disorder, obsessive–compulsive disorder and body dysmorphic disorder.
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This includes individual routine outcome measurement, which can be made available for routine
reporting and aggregation of outcome measures, as well as audit and review of effectiveness.
Specific monitoring tools and routine outcome measures are used.
[Adapted from NICE's guidelines on common mental health problems and social anxiety disorder]
Treatment for an anxiety disorder
Treatments for which responses are monitored include psychological interventions and
pharmacological treatment.
Equality and diversity considerations
The method of collecting self-reported treatment responses should be tailored to the person with
an anxiety disorder, according to their communication needs and preferences. It should be
culturally appropriate, accessible to people with additional needs such as physical, sensory or
learning disabilities, and to people who do not speak or read English. People with anxiety disorders
should have access to an interpreter or advocate if needed.
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Using the quality standard
Quality measures
The quality measures accompanying the quality statements aim to improve the structure, process
and outcomes of care in areas identified as needing quality improvement. They are not a new set of
targets or mandatory indicators for performance management.
See NICE's how to use quality standards for further information, including advice on using quality
measures.
Levels of achievement
Expected levels of achievement for quality measures are not specified. Quality standards are
intended to drive up the quality of care, and so achievement levels of 100% should be aspired to (or
0% if the quality statement states that something should not be done). However, NICE recognises
that this may not always be appropriate in practice, taking account of safety, choice and
professional judgement, and therefore desired levels of achievement should be defined locally.
Using other national guidance and policy documents
Other national guidance and current policy documents have been referenced during the
development of this quality standard. It is important that the quality standard is considered by
commissioners, providers, health and social care professionals, service users and carers alongside
the documents listed in development sources.
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Diversity, equality and language
During the development of this quality standard, equality issues have been considered and equality
assessments are available.
Good communication between health and social care professionals and people with anxiety
disorders is essential. Treatment, care and support, and the information given about it, should be
culturally appropriate. It should also be accessible to people with additional needs such as physical,
sensory or learning disabilities, and to people who do not speak or read English. People with
anxiety disorders should have access to an interpreter or advocate if needed.
Commissioners and providers should aim to achieve the quality standard in their local context, in
light of their duties to have due regard to the need to eliminate unlawful discrimination, advance
equality of opportunity and foster good relations. Nothing in this quality standard should be
interpreted in a way that would be inconsistent with compliance with those duties.
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Further explanation of the methodology used can be found in the quality standards process guide
on the NICE website.
Evidence sources
The documents below contain recommendations from NICE guidance or other NICE-accredited
recommendations that were used by the Quality Standards Advisory Committee to develop the
quality standard statements and measures.
Post-traumatic stress disorder (2018) NICE guideline NG116
Social anxiety disorder: recognition, assessment and treatment (2013) NICE guideline CG159
Common mental health problems: identification and pathways to care (2011) NICE guideline
CG123
Generalised anxiety disorder and panic disorder in adults: management (2011) NICE guideline
CG113
Obsessive-compulsive disorder and body dysmorphic disorder: treatment (2005) NICE
guideline CG31
Policy context
It is important that the quality standard is considered alongside current policy documents,
including:
National Audit of Psychological Therapies for Anxiety and Depression (2013) Healthcare
Quality Improvement Partnership
The competences required to deliver effective cognitive and behavioural therapy for people
with depression and with anxiety disorders (2007) Department of Health
Definitions and data sources for the quality measures
Improving Access to Psychological Therapies (IAPT) Data Set. NHS Digital
Children and Young People's IAPT Programme. NHS England
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Reference guide to consent for examination or treatment (second edition) (2009) Department
of Health
Adult psychiatric morbidity survey (2007) NHS Digital
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Related NICE quality standards
Transition between inpatient mental health settings and community or care home settings
(2017) NICE quality standard 159
Learning disabilities: identifying and managing mental health problems (2017) NICE quality
standard 142
Transition from children's to adults' services (2016) NICE quality standard 140
Antenatal and postnatal mental health (2016) NICE quality standard 115
Mental wellbeing of older people in care homes (2013) NICE quality standard 50
Depression in children and young people (2013) NICE quality standard 48
Patient experience in adult NHS services (2012) NICE quality standard 15
Service user experience in adult mental health services (2011) NICE quality standard 14
Depression in adults (2011) NICE quality standard 8
The full list of quality standard topics referred to NICE is available from the quality standards topic
library on the NICE website.
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Minor changes since publication
December 2018: Source guidance references have been updated to align this quality standard with
the NICE guideline on post-traumatic stress disorder.
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About this quality standard
NICE quality standards describe high-priority areas for quality improvement in a defined care or
service area. Each standard consists of a prioritised set of specific, concise and measurable
statements. NICE quality standards draw on existing NICE or NICE-accredited guidance that
provides an underpinning, comprehensive set of recommendations, and are designed to support
the measurement of improvement.
The methods and processes for developing NICE quality standards are described in the quality
standards process guide.
This quality standard has been incorporated into the NICE pathways for common mental health
disorders in primary care, generalised anxiety disorder, obsessive–compulsive disorder and body
dysmorphic disorder, panic disorder, post-traumatic stress disorder and social anxiety disorder.
ISBN: 978-1-4731-0450-1
Endorsing organisation
This quality standard has been endorsed by NHS England, as required by the Health and Social
Care Act (2012)
Supporting organisations
Many organisations share NICE's commitment to quality improvement using evidence-based
guidance. The following supporting organisations have recognised the benefit of the quality
standard in improving care for patients, carers, service users and members of the public. They have
agreed to work with NICE to ensure that those commissioning or providing services are made
aware of and encouraged to use the quality standard.
• Anxiety UK
• College of Mental Health Pharmacy
• Royal College of General Practitioners
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